🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

6,931 results for “The” Clear

  1. IMJUDO 20 mg/ml concentrate for solution for infusion., IMFINZI 50 mg/mL concentrate for solution for infusion.

    The George Institute

    Advanced stage intrahepatic biliary tract cancer (BTC)

    phase 2 small molecule active

    1 trial

  2. IMLIFIDASE

    The George Institute

    kidney trasplant

    phase 2 small molecule active

    1 trial

  3. IMMUNE RESET TO ALLOW ACCESS TO HLA-COMPATIBLE KIDNEY TRANSPLANTATION IN HYPERIMMUNIZED PATIENTS

    The George Institute

    chronic kidney disease, Hypersensitized patients

    phase 2 other active

    1 trial

  4. IMP1734

    Eikon Therapeutics

    Advanced Solid Tumor

    phase 2 small molecule active

    1 trial

  5. INCAGN02385, Retifanlimab (INCMGA00012), INCAGN02390

    Incyte

    In participants with PD-L1–positive and systemic therapy–naive R/M SCCHN.

    phase 2 small molecule active

    1 trial

  6. INDOCYANINE GREEN

    The George Institute

    Patients with primary invasive early breast cancer (T1-T2) that will undergo planned breast-conserving surgery

    phase 2 small molecule active

    1 trial

  7. INO-5401

    INOVIO PHARMACEUTICALS, INC.

    Urothelial Carcinoma

    phase 2 mab completed

    1 trial

  8. INT230-6

    INTENSITY THERAPEUTICS, INC.

    Breast Cancer

    phase 2 small molecule active

    2 trials

  9. INXN-2001

    Alaunos Therapeutics

    Melanoma

    phase 2 mab completed

    1 trial

  10. IO102-IO103, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    IO Biotech

    Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN), Metastatic Urothelial Bladder Cancer (mUBC), Metastatic Non-Small Cell Lung Cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  11. IOV-3001

    Iovance Biotherapeutics B.V.

    Unresectable Melanoma

    phase 2 mab active

    1 trial

  12. IOV-4001

    Iovance Biotherapeutics B.V.

    Unresectable Melanoma

    phase 2 mab active

    1 trial

  13. IRINOTECAN, FOLINIC ACID, FLUOROURACIL, DOMVANALIMAB, FLUOROURACIL, ZIMBERELIMAB

    CERO THERAPEUTICS HOLDINGS, INC.

    stomach cancer, Esophage, gastro-oesophageal junction adenocarcinoma

    phase 2 small molecule active

    1 trial

  14. ISA101b

    Regeneron UK Limited

    Squamous Cell Carcinoma of the Oropharynx

    phase 2 mab active

    2 trials

  15. ISIS 702843

    IONIS PHARMACEUTICALS INC

    Polycythemia Vera

    phase 2 small molecule active

    1 trial

  16. IV Remodulin

    United Therapeutics Europe Ltd

    Persistent Pulmonary Hypertension of the Newborn

    phase 2 small molecule terminated

    1 trial

  17. IVERMECTIN

    The George Institute

    Strongyloidiasis is caused by a parasite that is globally distributed in tropical and sub-tropical areas. Most patients with strongyloidiasis are asymptomatic or have mild symptoms with gastrointestinal disturbances, respiratory symptoms, and skin lesions. In situations of low defenses (patients under treatment with corticosteroids, organ transplant recipients or other situations) they can present serious complications with high mortality.

    phase 2 small molecule active

    1 trial

  18. IW-1701

    Cyclerion Therapeutics

    Sickle Cell Disease

    phase 2 small molecule completed

    1 trial

  19. IW-1973

    Cyclerion Therapeutics

    Diabetes Mellitus, Type 2

    phase 2 small molecule completed

    1 trial

  20. Ibrutinib

    Karyopharm Therapeutics Inc

    Lymphoma

    phase 2 small molecule active

    1 trial

  21. Ibrutinib

    United Therapeutics Europe Ltd

    Asymptomatic COVID-19 Infection Laboratory-Confirmed

    phase 2 small molecule terminated

    1 trial

  22. Ibrutinib 560 mg

    United Therapeutics Europe Ltd

    Mantle Cell Lymphoma

    phase 2 small molecule active

    1 trial

  23. Ibuprofen

    United Therapeutics Europe Ltd

    Tonsillectomy

    phase 2 small molecule completed

    1 trial

  24. Ibuprofen-PC

    Protalix BioTherapeutics

    Osteoarthritis

    phase 2 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources